Silence Therapeutics Narrows Loss as Trial Advances
Research-and-development expense fell to $9.1 million as earlier zerlasiran work rolled off.
Silence Therapeutics (SLN), an RNA therapeutics developer, narrowed its second-quarter loss as clinical progress coincided with lower operating expenses.
The results extended a cost reset that began after the company completed zerlasiran Phase 3-readiness work in 2025. Its net loss declined to $12.3 million from $15.0 million in the first quarter and $27.4 million a year earlier.
The loss equaled $0.09 a share, compared with $0.11 a share sequentially and $0.19 a share in the year-earlier period. Silence omitted collaboration revenue from its reported second-quarter financial metrics after recording $0.4 million from AstraZeneca in the first quarter, up from $0.1 million a year earlier.
R&D spending was unchanged from the first quarter and declined $8.4 million from $17.6 million a year earlier. The reduction was mainly due to the completion of zerlasiran readiness work and lower personnel costs.
General-and-administrative expense fell more sharply on a sequential basis, declining to $4.7 million from $7.0 million in the first quarter. The figure was also below the $5.1 million recorded a year earlier.
Clinical development advanced during the period. Silence completed dosing in June for all 48 phlebotomy-dependent polycythemia vera patients enrolled in the Phase 2 SANRECO trial, which had remained in progress at the end of the first quarter.
SLN365 and SLN098 are positioned for potential investigational new drug filings in 2027 after the company generated additional preclinical data scheduled for the second quarter. Its outstanding ordinary shares edged up by 35,340 during the quarter to 141,739,180 at June 30.